Decoding Roles at AstraZeneca: Unveiling Realities – At AstraZeneca (AZ), the postdoctoral position is essentially akin to a graduate student role. The next tier, Senior Scientist, requiring 2 years of work experience, mirrors a glorified postdoctoral position. In contrast to counterparts at other pharmaceutical companies like Novartis or BMS, AZ's Senior Scientists are expected to be independent contributors, engaged in lab benchwork while still participating in a plethora of departmental and online meetings – a testament to AZ's fondness for meetings. Adding to the challenges, the title of Team Leader at AZ lacks substantive recognition in the organizational matrix, offering no additional pay despite carrying the duties and responsibilities equivalent to an Associate Director or higher. AZ's practices underscore a form of "degree deflation," positioning individuals with advanced degrees below their qualifications. In contrast to "degree inflation," which demands higher degrees for traditionally lower-qualified roles.
Career Stagnation – Following the takeover of MedImmune, AZ consolidated various job levels into the generic title of Senior Scientist. While there may be upward movement within the pay band, the static title of Senior Scientist fails to project career advancement on one's resume. AZ's aversion to technician roles means that there are no junior staff to supervise, hindering the demonstration of increased responsibility on a resume. Interns, often limited to summer students or Master's students, offer no monetary compensation or recognition, further impeding career development.
Absence of Automation – In contrast to their peers at other pharmaceutical companies, Senior Scientists at AZ find themselves heavily engaged in lab work, reminiscent of a postdoctoral role. The absence of investment in automation compounds the issue, requiring highly qualified scientists to perform manual tasks like capping and uncapping vials and conducting labor-intensive measurements on a single-channel nanodrop.
Workload and Professional Development Challenges – The workload at AZ is notably intense, often involving the management of over 10 projects simultaneously. This workload frequently extends beyond regular working hours, demanding continuous efforts on evenings and weekends, rather than sporadic instances. While HR mandates dedicating 10% of working time to professional development—supported by a variety of online courses—practical challenges arise. Managers consistently allocate significant tasks, applying substantial downward pressure, leaving little room for the stipulated professional development time. When raising concerns, blame-shifting occurs, with the issue attributed to perceived time management deficiencies on the employee's part. Regrettably, the promotion landscape appears to favor white male candidates, a trend observed not only at AZ but also prevalent throughout the pharmaceutical industry.
AstraZeneca advocates for a "Speak up culture" in their Code of Ethics – We Do The Right Thing, encouraging individuals to "speak their minds and make it safe for others to do so." Unfortunately, this assertion appears to be misleading. Instead of fostering an open environment, the "Speak up culture" is used as a mechanism to identify individuals with a strong moral compass. Subsequently, these individuals may become targets for intervention by HR, Employee Relations, and Management.
Exit Interview – AZ’s deafening silence at the exit door speaks volumes. The lack of exit interviews paints a stark picture of a company seemingly uninterested in understanding or improving employee experiences. For potential employees, this red flag screams "closed culture" and begs the question: is employee well-being truly a priority, or just a superficial slogan?
PULSE Survey – Conducted every six months, the PULSE Survey serves as a tool to assess the performance of both managers and the company. AZ emphasizes the significance of this survey and asserts that managers can only view the percentage completion rate within their department. However, it is important to note that this claim is inaccurate. Managers do have access to the names of individuals who have taken the survey and can review their responses. Notably, negative feedback directed towards management is treated with utmost seriousness. Individuals expressing dissatisfaction become targets for elimination before the next PULSE survey, typically within the next six months. This strategic move aims to boost survey scores once the concerned individuals are no longer part of the workforce.
Internal reporting – Specifically regarding fraud and abuse through the online portal, is neither anonymous nor treated with the seriousness it implies. Upon identification, AstraZeneca initiates a process to manage individuals out of the company. For more serious cases deemed as "threats," the company conducts smear campaign leveling false accusations, resulting in immediate termination.
